Saladax Biomedical, Inc.   Report issue

For profit Phase 3 Phase 4
Founded: Bethlehem PA United States (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2011
NCT01326767
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (2)

cyclophosphamide (cytoxan) (1 trial)

docetaxel (taxotere) (1 trial)

Drugs in Phase 3 Trials (1)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3